00
000538.SHE Yunnan Baiyao Group Co Ltd
- Market cap
- CNY 97.7B
- P/E
- 18.7x
- P/B
- 2.38x
- ROE
- 16.0%
- Dividend yield
- 4.13%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 000538.SHE undervalued?
Graham number000538.SHE trades 40.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Yunnan Baiyao Group Co Ltd fundamental analysis
No fundamental analysis for Yunnan Baiyao Group Co Ltd yet.
Yunnan Baiyao Group Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Yunnan Baiyao Group Co Ltd
Yunnan Baiyao Group Co.,Ltd engages in the sale of pharmaceuticals, medicinal materials, health and daily chemical products in China. The company offers health products; traditional Chinese medicine used for pain management and anti-inflammation, including the Yunnan Baiyao aerosol, Yunnan Baiyao ointment, and Yunnan Baiyao band-aid; generic drugs and natural specialty medicines in various areas, such as physical fitness, respiratory ailments, cardiovascular health, gynecolo…
Full company profileYunnan Baiyao Group Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Yunnan Baiyao Group Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 22.4B | 24.3B | 27.0B | 29.7B | 32.7B | 36.4B | 36.5B | 39.1B | 40.0B | 41.2B | 43.0B |
| Gross Profit | 6.68B | 7.55B | 8.44B | 8.27B | 8.96B | 9.86B | 9.54B | 10.4B | 11.1B | 12.2B | 12.5B |
| Operating Income | 3.33B | 3.62B | 3.70B | 4.74B | 6.81B | 3.49B | 3.37B | 4.83B | 5.71B | 5.03B | 6.46B |
| EBITDA | 3.33B | 3.41B | 4.40B | 2.98B | 4.03B | 4.40B | 4.16B | 3.83B | 4.81B | 6.43B | 7.45B |
| Net Income | 2.92B | 3.14B | 3.49B | 4.18B | 5.52B | 2.80B | 3.00B | 4.09B | 4.75B | 5.15B | 6.43B |
| EPS | 2.00 | 2.16 | 1.96 | 2.34 | 3.08 | 1.56 | 1.90 | 2.29 | 2.66 | 2.89 | 3.60 |
| Balance Sheet | |||||||||||
| Total Assets | 24.6B | 27.7B | 54.1B | 49.7B | 55.4B | 52.3B | 53.3B | 53.8B | 52.9B | 54.3B | 54.9B |
| Total Liabilities | 8.74B | 9.56B | 14.0B | 11.6B | 17.1B | 13.9B | 14.8B | 13.9B | 14.0B | 14.1B | 14.5B |
| Shareholders' Equity | 15.7B | 18.0B | 39.8B | 37.9B | 38.1B | 38.2B | 38.5B | 39.9B | 38.8B | 40.0B | 40.3B |
| Cash & Short-term Investments | 5.29B | 9.42B | 29.8B | 21.8B | 26.5B | 23.6B | 15.5B | 14.4B | 13.4B | 9.11B | 7.63B |
| Total Debt | 1.80B | 1.80B | 3.60M | 917M | 2.13B | 1.98B | 2.14B | 1.92B | 616M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.98B | 1.16B | 1.55B | 2.10B | 3.83B | 5.22B | 3.21B | 3.50B | 4.30B | 4.60B | - |
| Capital Expenditure | 141M | 193M | 540M | 783M | 486M | 534M | 447M | 576M | 675M | 480M | 509M |
| Free Cash Flow | 2.84B | 962M | 2.09B | 1.32B | 3.34B | 4.69B | 2.76B | 2.93B | 3.62B | 4.12B | 5.99B |
| Ratios | |||||||||||
| ROE | 18.6% | 17.4% | 8.8% | 11.0% | 14.5% | 7.3% | 7.8% | 10.3% | 12.2% | 12.9% | 16.0% |
| ROA | 11.9% | 11.4% | 6.5% | 8.4% | 10.0% | 5.4% | 5.6% | 7.6% | 9.0% | 9.5% | 11.7% |
| Net Profit Margin | 13.0% | 12.9% | 12.9% | 14.1% | 16.8% | 7.7% | 8.2% | 10.5% | 11.9% | 12.5% | 14.9% |
| Debt to Equity | 0.11x | 0.10x | 0.00x | 0.02x | 0.06x | 0.05x | 0.06x | 0.05x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Yunnan Baiyao Group Co Ltd dividends
- Dividend yield
- 4.13%
- Forward dividend
- 1.58 CNY
- Payout ratio
- 78.2%
- Ex-dividend date
- Sep 24, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 4.03B | 2.26 | 78.2% |
| 2024 | CNY 5.94B | 3.33 | 125.1% |
| 2023 | CNY 2.75B | 1.54 | 67.1% |
| 2022 | CNY 2.11B | 1.34 | 70.5% |
| 2021 | CNY 4.94B | 2.74 | 176.1% |
| 2020 | CNY 3.83B | 2.14 | 69.5% |
| 2019 | CNY 2.59B | 1.45 | 61.8% |
| 2018 | CNY 205M | 0.11 | 5.9% |
| 2017 | CNY 931M | 0.64 | 29.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.4:1 on May 5, 2022.
Who owns Yunnan Baiyao Group Co Ltd
- Insiders 60.02%
- Institutions 9.05%
- Public & others 30.93%
- Shares outstanding 1.78B
- Free float 722M
Yunnan Baiyao Group Co Ltd company profile
- Company name
- Yunnan Baiyao Group Co Ltd
- Ticker
- 000538.SHE
- ISIN
- CNE0000008X7
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Nov 6, 1993
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 9,286
- Fiscal year end
- December
- Address
- No. 3686, Yunnan Baiyao Street, Kunming, China, 650500
- Phone
- 86 871 6622 6106
- Website
- yunnanbaiyao.com.cn
About Yunnan Baiyao Group Co Ltd
Yunnan Baiyao Group Co.,Ltd engages in the sale of pharmaceuticals, medicinal materials, health and daily chemical products in China. The company offers health products; traditional Chinese medicine used for pain management and anti-inflammation, including the Yunnan Baiyao aerosol, Yunnan Baiyao ointment, and Yunnan Baiyao band-aid; generic drugs and natural specialty medicines in various areas, such as physical fitness, respiratory ailments, cardiovascular health, gynecology, pediatrics, and others; medical devices; tea products; and pharmaceutical supply chain service solutions. Yunnan Baiyao Group Co., Ltd. was founded in 1902 and is based in Kunming, China.
Yunnan Baiyao Group Co Ltd management
9- Mr. Ming DongVice Chairman & President · born 1976
- Mr. Jia MaChief Financial Officer · born 1977
- Mr. Hongshen LiSenior Vice President · born 1978
- Mr. Sheng Li LiSenior Vice President · born 1973
- Mr. Shi ChenSenior Vice President · born 1980
- Mr. Tao HeSenior Vice President · born 1975
- Mr. Yinghui QianSecretary · born 1983
- Ms. Zhao Yun ZhuStrategic Scientist of Chinese Medicine · born 1954
- Jing XuAccounting Supervisor